RiociguatHypotension during off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1941卷 / 1期

关键词：

D O I：

10.1007/s40278-023-32583-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：321 / 321

相关论文

共 50 条

[1] SarilumabThrombocytopenia during an off-label use: case report
[J]. Reactions Weekly, 2020, 1833 (1) : 345 - 345
[2] IvabradineDizziness during off-label use: case report
[J]. Reactions Weekly, 2018, 1691 (1) : 169 - 169
[3] IvabradinePhosphenes during off-label use: case report
[J]. Reactions Weekly, 2018, 1688 (1) : 137 - 137
[4] AmikacinNephrotoxicity during off-label use: case report
[J]. Reactions Weekly, 2022, 1918 (1) : 36 - 36
[5] ThiamazoleFebrile neutropenia during off-label use: case report
[J]. Reactions Weekly, 2023, 1986 (1) : 413 - 413
[6] PosaconazoleAcute pancreatitis during off-label use: case report
[J]. Reactions Weekly, 2020, 1824 (1) : 244 - 244
[7] NarsoplimabLack of efficacy during off-label use: case report
[J]. Reactions Weekly, 2023, 1940 (1) : 337 - 337
[8] LevetiracetamWorsening of myoclonus during off-label use: case report
[J]. Reactions Weekly, 2018, 1693 (1) : 301 - 301
[9] CytisiniclineLactic acidosis during off-label use: case report
[J]. Reactions Weekly, 2020, 1828 (1) : 171 - 171
[10] MirtazapineVisual illusions during off-label use: case report
[J]. Reactions Weekly, 2021, 1836 (1) : 504 - 504

← 1 2 3 4 5 →